Avalon GloboCare Corp (AVCO)
Market Closed
10 Nov, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
0. 53
-0.1
-16.52%
$
5.26M Market Cap
- P/E Ratio
1.04% Div Yield
432,165 Volume
0 Eps
$ 0.63
Previous Close Day Range
0.52 0.65
Year Range
0.37 1.07
Want to track AVCO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
AVCO closed Thursday lower at $0.53, a decrease of 16.52% from Wednesday's close, completing a monthly increase of or $0.53. Over the past 12 months, AVCO stock gained .
AVCO is not paying dividends to its shareholders.
The last earnings report, released on Dec 31, 2016, missed the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Avalon GloboCare Corp has completed 1 stock splits, with the recent split occurring on Oct 18, 2016.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
AVCO Chart
Avalon GloboCare Corp Dividends
AVCO is not paying dividends to its shareholders.
Avalon GloboCare Corp Earnings
| 31 Dec 2016 Date | | - Cons. EPS | - EPS |
| 30 Sep 2016 Date | | - Cons. EPS | 0 EPS |
| 30 Jun 2016 Date | | - Cons. EPS | - EPS |
| 31 Mar 2016 Date | | - Cons. EPS | - EPS |
AVCO is not paying dividends to its shareholders.
| 31 Dec 2016 Date | | - Cons. EPS | - EPS |
| 30 Sep 2016 Date | | - Cons. EPS | 0 EPS |
| 30 Jun 2016 Date | | - Cons. EPS | - EPS |
| 31 Mar 2016 Date | | - Cons. EPS | - EPS |
Avalon GloboCare Corp (AVCO) FAQ
What is the stock price today?
The current price is $0.53.
On which exchange is it traded?
Avalon GloboCare Corp is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is AVCO.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 1.04%.
What is its market cap?
As of today, the market cap is 5.26M.
Has Avalon GloboCare Corp ever had a stock split?
Avalon GloboCare Corp had 1 splits and the recent split was on Oct 18, 2016.
Avalon GloboCare Corp Profile
| Real Estate - Services Industry | Real Estate Sector | David K. Jin CEO | NASDAQ (CM) Exchange | 05344R104 Cusip |
| US Country | 5 Employees | - Last Dividend | 5 Jan 2023 Last Split | 6 Dec 2016 IPO Date |
Overview
Avalon GloboCare Corp., along with its subsidiaries, is a diversified healthcare and real estate company based in Freehold, New Jersey. Founded in 2016, it operates both in the United States and China, managing commercial real estate properties. The company is notable for its involvement in the development and delivery of transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon GloboCare is actively engaged in advancing a variety of innovative therapeutic and diagnostic approaches, focusing particularly on cellular therapies, mRNA-based treatments, and exosome technology.
Products and Services
- AVA-001: An anti-CD19 CAR-T cellular therapy that has completed initial human clinical trials for treating relapsed/refractory (R/R) B-cell lymphoblastic leukemia. This indicates a significant step forward in Avalon's commitment to offering new cancer treatments.
- AVA-011: Currently in the IND-enabling process development stage, this therapy has completed pre-clinical laboratory studies. It is designed to generate cGMP-grade AVA-011 CAR-T cells, pushing forward the boundaries of cellular therapy for patients.
- mRNA-based Flash-CAR cell therapy platform: This platform represents Avalon's foray into the rapidly evolving field of mRNA therapeutics, focusing on developing next-generation cellular therapies.
- Avalon clinical-grade tissue-specific exosome (ACTEX): Focuses on leveraging exosome technology for therapeutic applications, showcasing Avalon’s commitment to exploring the potential of exosomes in medicine.
- AVA-Trap: A therapeutic program aimed at combating COVID-19 and other critical conditions associated with cytokine storms. This reflects Avalon's dedication to addressing immediate and pressing global health challenges.
- QTY-code protein design technology collaboration with MIT: This partnership focuses on the development of therapeutic and diagnostic targets, including the creation of a hemofiltration device to treat Cytokine Storm, showcasing the company's investment in innovative technologies.
- Co-development with Arbele Limited: This strategic collaboration aims to advance next-generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities, highlighting Avalon’s strategy of partnership in innovation.
- Strategic partnership with HydroPeptide, LLC: Engages in the co-development and commercialization of clinical-grade, exosome-based cosmeceutical, and orthopedic products, illustrating Avalon's versatility and its cross-sectoral collaborative efforts.
- Corporate research agreement with the University of Pittsburgh: This agreement centers around advancing Avalon’s product development efforts, emphasizing the company’s commitment to research and innovation in collaboration with leading academic institutions.
Contact Information
Address: 4400 US Highway 9 Ste 3100
Phone: 16467624517
Website: https://www.avalon-globocare.com
2025 © Marketlog. All Rights Reserved.
